Transderm Scop Related Published Studies
Well-designed clinical trials related to Transderm Scop (Scopolamine Transdermal)
Potential of pretreatment neural activity in the visual cortex during emotional
processing to predict treatment response to scopolamine in major depressive
disorder. [2013]
Randomized, double-blind comparison of oral aprepitant alone compared with
aprepitant and transdermal scopolamine for prevention of postoperative nausea and
vomiting. [2012]
A comparison of cinnarizine and transdermal scopolamine for the prevention of
seasickness in naval crew: a double-blind, randomized, crossover study. [2012]
Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans. [2011.12]
Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men. [2011.06]
Scopolamine produces larger antidepressant and antianxiety effects in women than in men. [2010.11]
The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects. [2010.11]
Scopolamine Produces Larger Antidepressant and Antianxiety Effects in Women Than in Men. [2010.08.25]
Transdermal scopolamine patch with odansetron for the control of nausea after uterine artery embolization compared with odansetron alone: results of a randomized placebo-controlled trial. [2010.07]
Management of drooling in disabled patients with scopolamine patches. [2010.06]
The efficacy of low-dose intranasal scopolamine for motion sickness. [2010.04]
Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. [2010.03.01]
Dose effects of triazolam and scopolamine on metamemory. [2010.02]
The effects of the glycine reuptake inhibitor R213129 on the central nervous
system and on scopolamine-induced impairments in psychomotor and cognitive
function in healthy subjects. [2010]
Replication of scopolamine's antidepressant efficacy in major depressive
disorder: a randomized, placebo-controlled clinical trial. [2010]
Effects of dimethylaminoethanol pyroglutamate (DMAE p-Glu) against memory deficits induced by scopolamine: evidence from preclinical and clinical studies. [2009.12]
Atropine, hyoscine butylbromide, or scopolamine are equally effective for the treatment of death rattle in terminal care. [2009.07]
Transdermal scopolamine patch in addition to ondansetron for postoperative nausea and vomiting prophylaxis in patients undergoing ambulatory cosmetic surgery. [2009.06]
A randomized, double-blind, multicenter trial comparing transdermal scopolamine plus ondansetron to ondansetron alone for the prevention of postoperative nausea and vomiting in the outpatient setting. [2009.05]
Specific impairments in visuospatial working and short-term memory following low-dose scopolamine challenge in healthy older adults. [2008.08]
The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine. [2008.07]
Transdermal scopolamine for prevention of intrathecal morphine-induced nausea and vomiting after cesarean delivery. [2007.09]
Relative bioavailability of scopolamine dosage forms and interaction with dextroamphetamine. [2007.07]
Differential effects of scopolamine and lorazepam on working memory maintenance versus manipulation processes. [2007.06]
Improvement of pulmonary function and dyspnea by tiotropium in COPD patients using a transdermal beta(2)-agonist. [2007]
Neutral and emotional episodic memory: global impairment after lorazepam or scopolamine. [2006.11]
Left prefrontal cortex control of novel occurrences during recollection: a psychopharmacological study using scopolamine and event-related fMRI. [2006.10.15]
Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. [2006.10]
Comparison of glucagon and scopolamine butylbromide as premedication for colonoscopy in unsedated patients. [2006.09]
Scopolamine induces impairments in the recognition of human facial expressions of anger and disgust. [2006.05]
The effect of transdermal scopolamine on the incidence and severity of postoperative nausea and vomiting in a group of high-risk patients given prophylactic intravenous ondansetron. [2006.04]
[Effect of esmolol on cardiovascular responses induced by scopolamine butylbromide] [2005.11]
Drugs, memory, and metamemory: a dose-effect study with lorazepam and scopolamine. [2005.11]
REM sleep and cortisol responses to scopolamine during depression and remission in women. [2004.09]
Effects of scopolamine on MEG spectral power and coherence in elderly subjects. [2003.10]
[Effects of treatment with redox agent, blood transfusion and scopolamine on 200 patients with severe chlorphenamidine poisoning] [2003.06]
Lorazepam and scopolamine: A single-dose comparison of effects on human memory and attentional processes. [2003.02]
Effect of subcutaneous butylscopolamine administration in the reduction of peristaltic artifacts in 1.5-T MR fast abdominal examinations. [2003.02]
Effects of scopolamine on matching to sample paradigm and related tests in human subjects. [2003]
Low dose transdermal scopolamine increases cardiac vagal tone in patients after acute myocardial infarction. [2002.05]
Verbal fluency facilitated by the cholinergic blocker, scopolamine. [2002.01]
Safety and efficacy of glucagon as a premedication for upper gastrointestinal endoscopy--a comparative study with butyl scopolamine bromide. [2002.01]
The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance. [2001.09]
Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo. [2001.05]
Acute dose-effects of scopolamine on false recognition. [2001.02]
Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers. [2001.01]
Scopolamine bioavailability in combined oral and transdermal delivery. [2001.01]
Influence of grapefruit juice on scopolamine pharmacokinetics and pharmacodynamics in healthy male and female subjects. [2000.11]
Scopolamine impairs memory performance and reduces frontal but not parietal visual P3 amplitude. [2000.02]
Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. [2000.01]
Scopolamine augments transient auditory 40-hz magnetic response in humans. [1999.12.24]
Effects of atropine and scopolamine on bradycardia and emetic symptoms in otoplasty. [1999.01]
Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration. [1998.08]
Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. [1998.03]
Low-dose transdermal scopolamine decreases blood pressure in mild essential hypertension. [1998.03]
[Clinical phase III study of cimetropium bromide (DA3177) on the pain with upper urinary calculus: a double-blind study in comparison with scopolamine butylbromide. DA3177 Study Group] [1997.07]
Differential response of rapid eye movement sleep to cholinergic blockade by scopolamine in currently depressed, remitted, and normal control subjects. [1997.05.01]
Effects of low-dose transdermal scopolamine on autonomic cardiovascular control in healthy young subjects. [1997.03]
Minimal effects of dextroamphetamine on scopolamine-induced cognitive impairments in humans. [1997.01.01]
[Usefulness of pirenzepine in the study of the upper digestive tract and the large intestine with double contrast media: comparison with scopolamine methylbromide] [1996.12]
The use of scopolamine in the treatment of detrusor instability. [1996.12]
Usefulness of transdermal scopolamine for vasovagal syncope. [1996.08.15]
Double blind placebo controlled trial of short term transdermal scopolamine on heart rate variability in patients with chronic heart failure. [1996.08]
Pirenzepine versus scopolamine methyl bromide in double-contrast barium enema study of large bowel. [1996.07]
Age-related decline in central cholinergic function demonstrated with scopolamine. [1996.05]
[Transdermal scopolamine for prevention of postoperative nausea and vomiting. No clinically relevant result in spite of reduced postoperative vomiting in general surgical and gynecologic patients] [1996.03]
Effect of low doses of scopolamine on RR interval variability, baroreflex sensitivity, and exercise performance in patients with chronic heart failure. [1996.03]
The effects of a benzodiazepine receptor antagonist beta-carboline ZK-93426 on scopolamine-induced impairment on attention, memory and psychomotor skills. [1996.02]
Effect of transdermal hyoscine on nausea and vomiting during and after middle ear surgery under local anaesthesia. [1996.01]
Cognitive effects of scopolamine in dementia. [1996]
The effects of scopolamine, lorazepam, and glycopyrrolate on classical conditioning of the human eyeblink response. [1995.12]
Caffeine attenuates scopolamine-induced memory impairment in humans. [1995.11]
Ocular effects of hyoscine in double dose transdermal administration and its reversal by low dose pyridostigmine. [1995.11]
Premedication with promethazine and transdermal scopolamine reduces the incidence of nausea and vomiting after intrathecal morphine. [1995.10]
Epidural scopolamine administration in preventing nausea after epidural morphine. [1995.09]
Scopolamine and lorazepam exert different patterns of effects in a test battery assessing stages of information processing. [1995.06]
Premenstrual syndrome: a double-blind controlled trial of desipramine and methylscopolamine. [1995.06]
Effect of transdermal hyoscine on nausea and vomiting after surgical correction of prominent ears under general anaesthesia. [1995.06]
Reduction of pain and nausea after laparoscopic sterilization with bupivacaine, metoclopramide, scopolamine, ketorolac, and gastric suctioning. [1995.05]
Bidirectional modulation of scopolamine-induced working memory impairments by muscarinic activation of the medial septal area. [1995.05]
Prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy. A prospective randomized study of metoclopramide and transdermal hyoscine. [1995.04]
Rectal versus intramuscular morphine-scopolamine as premedication in children. [1995.02]
Effects of the cholinomimetic SDZ ENS-163 on scopolamine-induced cognitive impairment in humans. [1995.02]
Prevention of nausea and vomiting with transdermal hyoscine in adults after middle ear surgery during general anaesthesia. [1994.12]
Effects of a single intravenous dose of scopolamine on the quantitative EEG in Alzheimer's disease patients and age-matched controls. [1994.12]
Preoperative transdermal scopolamine does not reduce the level of nausea and frequency of vomiting after laparoscopic cholecystectomy. [1994.08]
Transdermal scopolamine for the reduction of postoperative nausea in outpatient ear surgery: a double-blind, randomized study. [1994.08]
Pharmacological models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on word valence ratings, priming and recall. [1994.07]
Transdermal scopolamine for reduction of drooling in developmentally delayed children. [1994.06]
Usefulness and safety of pirenzepine in double-contrast study of upper gastrointestinal tract: comparison with scopolamine methylbromide. [1994.05]
Pramiracetam effects on scopolamine-induced amnesia in healthy volunteers. [1994.03]
Prevention of postoperative nausea and vomiting with transdermal hyoscine in children using patient-controlled analgesia. [1994.01]
Scopolamine effects on the pressor response to thyrotropin-releasing hormone in humans. [1994]
The effects of transdermal scopolamine on autonomic nervous activity during sleep. [1994]
Cardiovascular effects of Atenolol, scopolamine and their combination on healthy men in Finnish sauna baths. [1994]
Double-blind study with dipyrone versus tramadol and butylscopolamine in acute renal colic pain. [1994]
Scopolamine increases vagal tone and vagal reflexes in patients after myocardial infarction. [1993.11.01]
Effects of low dose transdermal scopolamine on heart rate variability in acute myocardial infarction. [1993.11.01]
Observer-blind study with metamizole versus tramadol and butylscopolamine in acute biliary colic pain. [1993.11]
Low doses of scopolamine increase cardiac vagal tone in the acute phase of myocardial infarction. [1993.08]
Effect of scopolamine on spontaneous yawning in men. [1993]
|
